prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Clinical Diagnosis & History: year old female with stage IV breast carcinoma, debulking surgery. Specimens Submitted: 1: SP: Right breast and axillary contents level 1. DIAGNOSIS: 1. BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY: - INVASIVE CARCINOMA, HISTOLOGIC GRADE II/III (MODERATE TUBULE. FORMATION) TO HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND SHAPE), MEASURING AT. LEAST 10 CM IN LARGEST DIMENSION GROSSLY. INVASIVE CARCINOMA SHOWS. MICROPAPILLARY FEATURES. FOCAL EXTRACELLULAR MUCIN IS ALSO NOTED. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID CRIBRIFORM. MICROPAPILLARY AND FLAT TYPES, WITH HIGH NUCLEAR GRADE, AND EXTENSIVE. NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN ALL FOUR QUADRANTS. - THE DCIS IS LOCATED IN ALL FOUR QUADRANTS. - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS. - THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION. - INVASIVE CARCINOMA IS CLOSE (LESS THAN 0.1 CM) FROM THE NEAREST DEEP. MARGIN. THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. FOCAL CHANGES OF PRIOR PROCEDURE ARE NOTED IN THE AXILLARY TAIL. - METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2) ADDITIONAL SECTIONS OF THE AXILLARY TISSUE HAVE BEEN SUBMITTED AND. THE FINDINGS WILL BE REPORTED IN AN ADDENDUM. - NUMEROUS FOCI OF METASTATIC CARCINOMA ARE NOTED IN THE AXILLARY SOFT. TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM. Immunohistochemical stains were performed on formalin-fixed tissue with. the following results for invasive carcinoma (block 1-8): ESTROGEN RECEPTOR. 90% nuclear staining with strong. intensity. PROGESTERONR RECERTOR. Negative (no nuclear staining). HER2. Equivocal (focal 2+). FISH will be performed. (5% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). The carcinoma is positive for E-cadherin, supporting lobular. differentiation. Comment: Controls are satisfactory. Ventana' a PATHWAY anti-HER-2/neu is. an FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed. against the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25(1):118-145). The ER and PR rabbit monoclonal antibodies are also FDA. approved. Some of the imnunohistochemistry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: M.D. M.D. 1) The specimen is received fresh labeled, "right breast and axillary. contents level 1",. It consists of a breast with attached. axillary contents. The breast measures 20 x 15 x 5 cm with overlying skin. ellipse measuring 18 x 7 x 0.2 cm. Situated centrally on the skin surface is. a. fixed, and retracted nipple measuring 1.5 x 1.0 x 1.0 cm. The surrounding. skin is markedly thickened (up to 0.6 cm) . A suture demarcates the axillary. contents which measures 7 x 5 x 2 cm. The posterior surface of the breast is. inked black and the anterior blue. Part of the posterior surface of the. breast is covered by dark red skeletal muscle, measuring 11 x 4 x 0.5 cm. The specimen is serially sectioned to reveal an irregular tumor bed (10 x. 8.3 x 5.1 cm) with poorly defined white, firm and tan areas. The tumor bed. occupies almost the entire breast volume, extending throughout all four. quadrants. The tumor bed is located 0.2 cm from the posterior margin, 0.3 cm. from the anterior margin, and 0.5 cm from the skeletal muscle. The remaining. breast tissue shows yellow fatty areas with foci of fibrosis. The axillary. tissue is dissected to reveal 13 possible lymph nodes, ranging in size from. 0.4 cm to 1.2 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. The specimen is photographed. Tissue is. submitted to TPS. Summary of sections: N - nipple, nipple base and tumor. s - thickened skin. PM - posterior margin. AM - anterior margin. DSM - deep skeletal muscle. T - tumor central region and closest margins, continuous cross sections,. taken from medial to lateral. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 - axilla, level one lymph nodes. AX axillary tail, entirely submitted. Summary of Sections: Part 1: SP: Right breast and axillary contents level 1. Block. Sect. Site. PCs. 1. AM. 1. 11. ax. 11. 1. DSM. 1. 9. L1. 9. 2. LIQ. 2. 2. LOQ. 2. 3. N. 3. 1. PM. 1. 1. s. 1. 10. T. 10. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: By: 1. Addendum Diagnosis. PART #1. RIGHT BREAST AND AXILLARY CONTENTS: THE REMAINING AXILLARY TISSUE IS ENTIRELY SUBMITTED. NO ADDITIONAL LYMPH. NODES ARE IDENTIFIED. ,MD.

expanded version (tokens=2130) : 
 Histological Classification: The breast cancer is described as invasive with histologic grade II/III to III/III, with micropapillary features and extensive necrosis. Ductal carcinoma in situ (DCIS) is also identified as being solid, cribriform, micropapillary, and flat types, with high nuclear grade and extensive necrosis. The subtype is LumA.

Nuclear and Histologic Grade: The invasive carcinoma is of nuclear grade III/III (marked variation in size and shape), with moderate to no tubule formation, while the histologic grade of the invasive carcinoma is II/III to III/III. 

Lymphovascular Invasion and Metastasis: Vascular invasion is present in the report, and metastatic carcinoma is reported to be present in two out of two level I lymph nodes. Numerous foci of metastatic carcinoma are noted in the axillary soft tissue. 

Receptor Status and Ancillary Testing Results: Estrogen receptor is reported at 90% nuclear staining with strong intensity, while progesterone receptor is negative (no nuclear staining). HER2 is said to be equivocal (focal 2+), and FISH is to be performed, as 5% of invasive tumor cells exhibit complete membranous staining. The carcinoma is positive for E-cadherin, supporting lobular differentiation. The ancillary testing included formalin-fixed tissue Immunohistochemical stains, the results of which are mentioned above. Overall

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2304) : 
 The report describes invasive carcinoma, histologic grade II/III to III/III with micropapillary features and extensive necrosis. Ductal carcinoma in situ (DCIS) is also identified. Receptor status shows estrogen receptor at 90% and progesterone receptor to be negative. HER2 is equivocal. Vascular invasion is reported with metastatic spread to two level I lymph nodes and multiple foci of metastatic carcinoma in the axillary soft tissue. There is a focal attachment to deep margin with tumor proximity of <0.1 cm. The non-neoplastic breast tissue is unremarkable.

